2022 ASCO Annual Meeting I

ABSTRACT

The proceedings contain 5148 papers. The topics discussed include baseline GP2 immune response as an independent prognostic factor in a phase IIb study evaluating HER2/neu peptide GP2 (GLSI-100) versus. GM-CSF alone after adjuvant trastuzumab in HER2-positive women with breast cancer;fertility preservation decisions and outcomes of young women with breast cancer;adjuvant trastuzumab and vinorelbine (TV) for early-stage HER2+ breast cancer;Outcomes of neoadjuvant (NA) and adjuvant (A) chemotherapy in geriatric patients with stage I-III triple-negative breast cancer (TNBC) a single institution experience;Telehealth delivered Tai Chi intervention for managing aromatase inhibitor-induced arthralgia in breast cancer patients TaiChi4Joint during the COVID-19 pandemic a pilot study;a prospective real-world study to assess the effectiveness and safety of trastuzumab biosimilar in the adjuvant treatment of HER2-positive breast cancer preliminary safety results;effectiveness of chemotherapy on prognosis of elderly breast cancer a retrospective cohort study based on SEER database;and prognostic role of the stromal tumor-infiltrating lymphocytes (TILs) in women with early ER+/HER2+ breast cancer (BC) in whom adjuvant chemotherapy (ChT) was omitted.